Seragen, Sandoz Pharma Ltd. deal

Sandoz exercised its option to license certain SRGN patents relating to transplantation. Included in the license is U.S. Patent No. 5,011,684, which covers the use of interleukin-2 (IL-2) receptor targeted monoclonal antibodies to treat transplant rejection and other immune disorders. Sandoz received the option in April (see BioCentury April 15). ...